A driveshaft containment system and a method of its use. In preferred embodiments, the invention takes the form of a two component system including a first component mounted to a device such as a differential housing, coupled to driveshaft, and a second component comprising a tubular driveshaft containment housing. A driveshaft containment ring is preferably mounted to the forward end of the tubular housing which in turn is provided with a mechanism at its rearward end for rotationally engaging and disengaging the first component. The first and second components are also provided with a mechanism for preventing relative rotational movement of the first and second components while engaged with one another.

An aluminum alloy propeller shaft including a tube made of an aluminum alloy, and a pair of yoke members made of an aluminum alloy, the yoke members including cylindrical base portions friction-welded to opposite end portions of the tube, each of the yoke members including a tip end portion having a pair of bearing retaining holes aligned with each other in a radial direction of the base portion. Variation in length between a central axis of the bearing retaining holes in one of the yoke members and a central axis of the bearing retaining holes in the other yoke member with respect to a reference length is set within a range of from +2.0 mm to −2.0 mm. A friction welding process of producing an aluminum alloy propeller shaft, including a friction step, a position displacement detection step, a rotation stop step and an upset step.

In a scroll compressor of the present invention, a fixed scroll 11 and an orbiting scroll 12 are meshed with each other such that spiral laps of the fixed scroll 11 and the orbiting scroll 12 inwardly face each other, an Oldham ring 26 is provided between the main bearing member 19 and the orbiting scroll 12, and a key portion of the Oldham ring 26 is inserted into a key groove 19a of the main bearing member 19. Grooves 19b are formed in Oldham ring 26 sliding surfaces on both sides of the key groove 19a. According to this configuration, the Oldham ring 26 and the main bearing member 19 can be restrained from coming into contact with each other in the vicinity of the bearing key groove 19a, and restrained from vibrating, and it is possible to provide an inexpensive scroll compressor of low noise.

A coupling for connecting a rotating tube cleaning shaft to a tube cleaning machine where high pressure fluid is pumped through the coupling, where the coupling is sealed to contain the high pressure fluid, and where a machine driven rotary flexible shaft passes through the coupling.

A shaft for transmitting torques includes a hollow shaft made of fiber-reinforced plastic. A flange which can be used to connect the hollow shaft to a driving or driven machine part is fastened at least to one end of the hollow shaft. The flange is fastened to the hollow shaft via a number of screw connections. Each screw connection includes a screw and a nut. The shank of the screw projects in the direction of the hollow shaft through an opening in the flange that is arranged in the connection region between the end edge of the hollow shaft and the flange. The shank extends at least partially inside the shell of the hollow shaft and engages with the nut arranged on the hollow shaft. The head of the screw is supported on that side of the flange opposed to the hollow shaft.

Beamformer coefficients may include a plurality of sets of theoretical statistical data for theoretical signals. Each theoretical signal may have its own particular attributes. The statistical data may be used in computing beamformer coefficients for application by a beamformer to signals received at a device. Signals are received at an input of the device. A respective plurality of weights is determined, for the theoretical statistical data sets, based on an analysis of the extent to which the signals have the particular attributes of the theoretical signals. The theoretical are retrieved, and a statistical data set is calculated for the signals by performing a weighted sum of the theoretical statistical data sets using the determined respective plurality of weights. Beamformer coefficients are computed based on the calculated statistical data set for the signals, which are used by a beamformer to the signals for generating a beamformer output.

Audio signals are processed for use in a communication event. A data store may be queried to obtain an indication of an echo direction, which relates to a direction from which audio signals output from the audio output are likely to be received at a microphone array (plurality of microphones) of a device. Beamformer coefficients of an adaptive beamformer of the device are determined in dependence upon the received indication of the echo direction. Audio signals are received at the microphone array. The adaptive beamformer applies the determined beamformer coefficients to the received audio signals, thereby generating a beamformer output for use in the communication event. The beamformer coefficients are determined such that echo suppression is applied to audio signals received at the microphone array from the indicated echo direction.

A system and method is provided for energizing and managing digitally-controlled devices at different levels of granularity, to achieve desired power use characteristics. At the lowest level, a digitally-controlled device is energized using a variable load-sensing adaptive control (VLSAC). Operation of the device is controlled using digital signals input to the device, so that limits on parameters, such as power consumption are met. A plurality of VLSACs can be coupled to a power distribution unit (PDU), which is controlled to achieve desired levels for selected parameters, set for the PDU. Multiple PDUs can be coupled to a power conversion and regulation unit (PCRU), which can be controlled by a master control to achieve a desired power profile for an entire facility, enabling the facility to meet requirements of a utility supplying the power and thus, reducing operational costs. The VLSACs and PCRU include high efficiency power sources having low distortion.

A secondary or “sidebar” display within a process control environment may provide several small applications to allow business managers, engineers, maintenance personnel, or other non-operator personnel to organize and manage process control system information and to display selected diagnostics and summary information or “key operating parameters” for the process control system. Further, sidebar applications may communicate with other applications that are executing on a non-operator user's workstation to, thereby, retrieve information related to tasks that the user is currently completing. The sidebar application may then determine whether certain process control information may be useful for the main task the user is completing and display that process control information within the sidebar.

A method models a defect management routine. Both the modeling and a handling are executed within a manufacturing execution system. During an engineering phase: modeling the production process and creating a library of possible defect types which may occur; assigning the defect types to at least one defect group; creating a library of defect specifications; creating a library of defect type specification details; creating at least one runtime defect criteria that is used to link the defect type to a certain production volume; and creating a runtime defect measurement routine that monitors a corrective measure. During a runtime production phase evaluating the product produced; identifying the respective defect type out of the library of defect types; and using the identified defect type to determine a corrective measure, a runtime defect criteria identifying the resource causing the defect type, a production volume, and to run the respective runtime defect management routine.

Provided are a home network system and a method for an autonomous mobile robot to travel along a shortest travel route. The home network system capable of home automation includes a plurality of beacons for sensing a user located in a cell coverage area and for transmitting resulting sensing information of the user; an autonomous mobile robot for executing travel to reach the user based on provided travel route information; and a home server for calculating a travel route along which the autonomous mobile robot can easily reach the user based on the sensing information of the user transmitted from the beacons, and for providing the travel route to the autonomous mobile robot. Therefore, the autonomous mobile robot may reach the user by the shortest travel route and thus reducing energy loss.

An information processing apparatus for performing recognition processing by a recognizer for a position and orientation of a work subject to undergo work by a working unit of a robot arm. The information processing apparatus including an obtaining unit adapted to obtain, for each of a plurality of positions and orientations of the work subject, a position and an orientation of the working unit in which the working unit can perform the work, and a restriction unit adapted to restrict a position and an orientation of the work subject used in the recognition processing by the recognizer to a position and an orientation of the work subject corresponding to the position and the orientation of the working unit that have been obtained by the obtaining unit.

Black disazo dyes of general formula (V) wherein A is a moiety of formula (VI) or of formula (VII) and B is a moiety of formula (VII) or of formula (IX) and wherein M, R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, R14, R15, R16, R17, R18, R19, R20, R21, R22, R23, and R24, are as defined in the specification, are excellent black dyes for dying and printing cellulose containing materials and textile materials and, in particular, for preparation of recording liquids for ink jet printing and for writing utensils.

The present invention relates to a novel polymeric composition comprising a novel polymer having two or more repeat units and a terminus having the structure (1): wherein R1 represents a C1-C20 substituted or unsubstituted alkyl group, w is a number from 1-8, X is oxygen (O) or nitrogen (N), and Rd is a reactive group. The invention also relates to a process for forming a pattern using the novel polymeric composition. The invention further relates to a process of making the novel polymer.

Complexes of heterocyclic radionuclides are prepared based upon ligands having substituted pyridyl and imidazolyl groups. The ligands are bifunctional, having amino acid residues that may act as a linker to a bioactive molecu le, and a tridentate chelator that may complex the radionuclide. The bioactive molecule may be a peptide or somatostatin.

The present invention relates to lithium salt-containing rare earth halide solutions in aprotic solvents, processes for production thereof and also use thereof.

The invention relates to a bonding product suitable as a carrier for medicinal substances and to the compound derived therefrom that carries medicinal substances. The invention further relates to a process and device for preparing such bonding products and compounds. Further, the invention relates to a pharmaceutical composition containing such bonding products and compounds, and to the use thereof for preparing an infusible medicament for treating a disease.

A light absorption anisotropic film, wherein content of a liquid crystalline non-colorable low molecular weight compound is 30% by mass or less; and which is obtained by fixing the alignment of a dichroic dye composition comprising at least one type of azo-based dichroic dye having nematic liquid crystallinity; and shows a diffraction peak derived from a periodic structure in a direction parallel to the alignment axis on measurement of X-ray diffraction. The light absorption anisotropic film is high in dichroism.

A cycloalkyl triamine pentacarboxylate compound coordinating to a metal ion to form a high stability metal complex in serum is provided. The metal complex of the present invention can be used as a contrast agent for magnetic resonance imaging (MRI).

This invention relates to novel Ln(III) complexes of pybox, and methods of making the same. The present invention also relates to a method of use of pybox as a chelating moiety and sensitizer for Ln(III) ion luminescence. Derivatives of pybox and methods of making the same are also provided.

Disclosed is a spectrofluorimetrically detectable luminescent composition consisting essentially of at least one energy transfer acceptor lanthanide(III) complex having an emission spectrum maximum in the range from 300 to 2000 nanometers and a luminescence-enhancing amount of at least one energy transfer donor selected from the group consisting of a fluorophore, a lumiphore, an organic compound, a salt of an organic ion, a metal ion, a metal ion complex, or a combination thereof. Such energy transfer donor enhances the luminescence of at least one energy transfer acceptor lanthanide(III) complex, with the conditions that the emission spectrum of any energy transfer donor differs from that of its energy transfer acceptor lanthanide(III) complex; and such energy transfer donor can be dissolved to form a unitary solution in a solvent having an evaporation rate at least as great as that of water.

It is an object of the present invention to provide antimicrobial metallodrugs comprising an antimicrobial peptide (“AMP”) and/or an antibiotic covalently bound to a metal binding moiety. These metallodrugs combine a metal binding domain which typically catalyzes oxido-reductase chemistry or acts as a Lewis-Acid catalyst, with a member of a diverse class of antimicrobial agents currently validated in preclinical and clinical settings for the treatment of a broad spectrum of pathogenic organisms.

Disclosed is a process for preparing a polyester or copolymer containing ester functionalities. The process can comprise: providing an optionally substituted lactone having a ring size of from 6 to 40 carbon atoms; andsubjecting said lactone to metal mediated ring-opening polymerization using as catalyst a compound according to general formula (I): wherein M can be Al, Cr, Mn and Co;X and X' are independently a heteroatom;Y and Y' can be, independently, selected from O, N, S, P, C, Si, and B;Z can be selected from hydrogen, borohydrides, aluminum hydrides, carbyls, silyls, hydroxide, alkoxides, aryloxides, carboxylates, carbonates, carbamates, amidos, thiolates, phosphides, and halides;L1 and L2 can be independently an organic ligand linking X and Y together and linking X' and Y' together, respectively; andL3 is an optional organic ligand linking Y and Y' together.

The purpose of the present invention is to provide novel liquid crystalline compounds that are capable of inducing phase transition by a light stimulus and are useful in the display, optoelectronics, and photonics field. The present invention relates to the liquid crystalline compounds represented by general formula (1): wherein R1, R2 and R3 are independently selected from the group consisting of hydrogen, alkyl, alkoxyl, alkoxycarbonyl, alkoxycarbonyloxy, alkanoyl, alkanoyloxy, alkoxyphenyl, and N-alkylaminocarbonyl, and n is an integer.

Chelators of the formulae (I), (II) and (III) and tricarbonyl complexes of radioisotopes of Tc and Re bound to them, for use in myocardial imaging.

The present invention relates to compounds suitable as modulators of protein misfolding and/or protein aggregation. The compounds are particularly suitable as inhibitors of amyloid aggregate formation and/or modulators of amyloid surface properties, and/or as activators of degradation or reduction of amyloid aggregates.

The rare-earth complex of the present invention has high luminous efficiency, since it has a structure represented by the following general formula (I):

Described herein are pharmaceutical compositions and medicaments, and methods of using such pharmaceutical compositions and medicaments in the treatment of cancer.

The present invention relates to a method of differentially diagnosing different types of dementia. In particular, the method relates to the use of specific SPECT tracers for differentially diagnosing Alzheimer's disease, Lewy-Body Dementia, and Frontotemporal Dementia.

A spent fuel reprocessing method including the steps of partitioning U and Pu(III) in a solvent by solvent extraction and subsequently polishing the solvent in a neptunium rejection operation for removing Np therefrom. The solvent obtained from the neptunium rejection operation (the polished solvent or NpA solvent product) is then recycled to a U/Pu partitioning operation. The method enables a reduction in solvent feed and solvent effluent volumes.

The present invention concerns a process for dissolving ruthenium deposits that are present on a surface and a process for decontaminating the internal circuits of nuclear fuel reprocessing plants using the said dissolution process. The process according to the invention comprises bringing the said surface into contact with an aqueous solution of perruthenate, with the said aqueous solution having a pH equal to or greater than 12, so that the ruthenium is oxidised.

This invention is provided for improvement of corrosion-resistant property of a crucible and for promotion of safety in a pyrochemical reprocessing method for the spent nuclear fuel. The spent nuclear fuel is dissolved in a molten salt placed in the crucible. In a pyrochemical reprocessing method, the nuclear fuel is deposited, and the crucible (2) is heated by induction heating. Cooling media (5, 6) are supplied to cool down, and a molten salt layer (7) is maintained by keeping balance between the heating and the cooling, and a solidified salt layer (8) is formed on inner wall surface of the crucible.

Decontamination of nuclear facilities is necessary to reduce the radiation field during normal operations and decommissioning of complex equipment. In this invention, we discuss gel and foam based diphosphonic acid (HEDPA) chemical solutions that are unique in that these solutions can be applied at room temperature; provide protection to the base metal for continued applications of the equipment; and reduce the final waste form production to one step. The HEDPA gels and foams are formulated with benign chemicals, including various solvents, such as ionic liquids and reducing and complexing agents such as hydroxamic acids, and formaldehyde sulfoxylate. Gel and foam based HEDPA processes allow for decontamination of difficult to reach surfaces that are unmanageable with traditional aqueous process methods. Also, the gel and foam components are optimized to maximize the dissolution rate and assist in the chemical transformation of the gel and foam to a stable waste form.

Materials and methods of making low-sintering-temperature glass waste forms that sequester radioactive iodine in a strong and durable structure. First, the iodine is captured by an adsorbant, which forms an iodine-loaded material, e.g., AgI, AgI-zeolite, AgI-mordenite, Ag-silica aerogel, ZnI2, CuI, or Bi5O7I. Next, particles of the iodine-loaded material are mixed with powdered frits of low-sintering-temperature glasses (comprising various oxides of Si, B, Bi, Pb, and Zn), and then sintered at a relatively low temperature, ranging from 425° C. to 550° C. The sintering converts the mixed powders into a solid block of a glassy waste form, having low iodine leaching rates. The vitrified glassy waste form can contain as much as 60 wt % AgI. A preferred glass, having a sintering temperature of 500° C. (below the silver iodide sublimation temperature of 500° C.) was identified that contains oxides of boron, bismuth, and zinc, while containing essentially no lead or silicon.

A method for recovery of residual actinide element from chloride molten salts that are formed after electro-refining and/or electro-winning of a spent nuclear fuel and include actinide elements and rare-earth elements is provided. The method comprises conducting electrolysis using a liquid cadmium cathode (LCC) in the chloride molten salt that is formed after electro-refining and/or electro-winning of a spent nuclear fuel and contains rare-earth elements and actinide elements; electro-depositing the actinide elements contained in the chloride molten salt on the LCC in order to reduce a concentration of the actinide elements; and adding a CdCl2 oxidant to the chloride molten salt containing the LCC-metal alloy in order to oxidize the rare-earth elements co-deposited on the LCC, thereby forming the rare-earth chlorides in the chloride molten salt.

A method for design of a fuel assembly for nuclear reactors, including structural components made from zirconium alloy: the mean uniaxial tensile or compressive stress to which the components are subjected during the assembly life is calculated, the zirconium alloy of which the components are made is selected according to the following criteria: those components subjected to an axial or transverse compressive stress of between −10 et −20 MPa are made from an alloy with a content of Sn between Sn=(=0.025σ−0.25)% and Sn=−0.05σ%: those components subjected to such a stress of between 0 et −10 MPa are made from an alloy the Sn content of which is between Sn=traces and Sn=(0.05σ+1)%: those components subjected to such a stress of between 0 and +10 MPa are made from an alloy the Sn content of which is between Sn=0.05% and Sn=(0.07σ+1)%: and those components subjected to such a stress of between +10 and +20 MPa are made from an alloy the content of SN of which is between 0.05% and 1.70%. A fuel assembly made according to the method.

The invention relates to a polypeptide having a mutation at one or more position corresponding to T219 of SEQ ID NO: 55, wherein the polypeptide has at least 50% sequence identity with SEQ ID NO: 55, and wherein the polypeptide has permease activity.

Described herein is a composition useful for inducing expression of genes whose expression is under control of an inducible promoter sequence and methods for the compositions preparation and use.

Provided herein are pharmaceutical formulations containing exendins, exendin agonists, or exendin analog agonists that are administered at therapeutic plasma concentration levels over a sustained period of time to lower total cholesterol levels; to lower LDL-cholesterol levels; to lower triglyceride levels; to treat dyslipidemia; to treat and slow the progression of atherosclerosis; and to treat, prevent, and reduce the risk of heart attacks and strokes in patients. In the pharmaceutical formulations and methods of the invention, the exendin may be exendin-4, an exendin-4 agonist, or an exendin-4 analog agonist. The pharmaceutical formulations may be polymer-based pharmaceutical formulations that may be administered once weekly. An exemplary pharmaceutical formulation comprises 5% (w/w) of exenatide, about 2% (w/w) of sucrose, and about 93% (w/w) of a poly(lactide-co-glycolide) polymer, wherein the poly(lactide-co-glycolide) polymer is in the form of microspheres encapsulating the exenatide.

The present invention relates to antibody molecules against anticoagulants, in particular dabigatran, and their use as antidotes of such anticoagulants.

Potent compounds having combined antioxidant, anti-inflammatory, anti-radiation and metal chelating properties are described. Short peptides having these properties, and methods and uses of such short peptides in clinical and cosmetic applications are described.

The invention provides cyclo[{4-(NH2—C2H4—NH—CO—O—)Pro}-Phg-DTrp-Lys-Tyr(4-Benzyl)-Phe], optionally in protected form, or a pharmaceutically acceptable salt or complex thereof, which has interesting pharmaceutical properties.

Cyclic CRF antagonist peptides having improved properties of “drugability”. The peptides are 33 residues in length with a lactam bond between the residues in position 22 and 25; however, they may be N-terminally shortened by up to 3 residues.

To provide a diagnostic and therapeutic medicament, a bombesin analog peptide antagonist conjugate is provided which has general Formula (I), wherein A is a metal chelator comprising at least one radionuclide metal, B is a spacer linked to N-terminal of C or a covalent bond and C is a bombesin analog peptide antagonist having a sequence as claimed, where further x is an integer from 1 to 3 and n is an integer from 1 to 6. [A-(B)n]x—C (I)

A method of producing a molecularly-imprinted material comprises synthesizing a peptide, oligosaccharide or oligonucleotide on a disposable surface modified support to produce a support surface-attached peptide, oligosaccharide or oligonucleotide, providing a selected monomer mixture, contacting the monomer mixture with the support surface-attached peptide, oligosaccharide or oligonucleotide, initiating polymerisation or at least one crosslinking reaction, dissolving or degrading the support surface-attached peptide, oligosaccharide or oligonucleotide and support, and obtaining molecularly imprinted material.

The present invention relates to binding molecules that specifically bind to the human Fc gamma receptor expressed on the surface of natural killer (NK) cells and macrophages (i.e. FcγRIIIA), and in particular binding molecules that specifically bind the A form FcγRIII but do not bind to the B form of FcγRIII, as well as to the use of such binding molecules in the diagnosis and treatment of disease. The invention further extends to polynucleotides encoding such binding molecules, host cells comprising such polynucleotides and methods of producing binding molecules of the invention using such host cells.

The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease.

The present invention relates to CX3CR1-binding polypeptides, in particular polypeptides comprising specific immunoglobulin domains. The invention also relates to nucleic acids encoding such polypeptides; to methods for preparing such polypeptides; to host cells expressing or capable of expressing such polypeptides; to compositions comprising such polypeptides; and to uses of such polypeptides or such compositions, in particular for prophylactic, therapeutic and diagnostic purposes.

Human antibodies, preferably recombinant human antibodies, that specifically bind to human interleukin-12 (hIL-12) are disclosed. Preferred antibodies have high affinity for hIL-12 and neutralize hIL-12 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hIL-12 and for inhibiting hIL-12 activity, e.g., in a human subject suffering from a disorder in which hIL-12 activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.

The present disclosure describes antibodies that target HM1.24. In various aspects, the antibodies have specific CDR, variable, or full length sequences, have modifications with the parent antibody, or include at least one modification relative to a parent antibody that alters affinity to an FcγR or alters effector function as compared to the parent antibody. Nucleic acids encoding the antibodies and methods of using the antibodies are also disclosed.